BCM
ARKG icon

Brookstone Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Brookstone Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
44,330
+4,979
+13% +$159K 0.02% 514
2026
Q1 		$1.04M Sell
39,351
-4,358
-10% -$128K 0.01% 629
2025
Q4 		$1.27M Sell
43,709
-6,580
-13% -$198K 0.01% 567
2025
Q3 		$1.4M Sell
50,289
-2,389
-5% -$60.4K 0.02% 526
2025
Q2 		$1.28M Sell
52,678
-2,628
-5% -$57.6K 0.02% 506
2025
Q1 		$1.15M Sell
55,306
-3,161
-5% -$79.4K 0.02% 524
2024
Q4 		$1.38M Sell
58,467
-8,017
-12% -$197K 0.02% 445
2024
Q3 		$1.7M Sell
66,484
-5,954
-8% -$152K 0.03% 404
2024
Q2 		$1.94M Sell
72,438
-8,254
-10% -$208K 0.03% 374
2024
Q1 		$2.32M Buy
80,692
+1,959
+2% +$58.9K 0.04% 336
2023
Q4 		$2.58M Sell
78,733
-11,624
-13% -$316K 0.05% 293
2023
Q3 		$2.16M Sell
90,357
-9,628
-10% -$315K 0.05% 291
2023
Q2 		$3.31M Sell
99,985
-4,483
-4% -$141K 0.07% 246
2023
Q1 		$3.21M Sell
104,468
-3,711
-3% -$115K 0.06% 249
2022
Q4 		$3.06M Sell
108,179
-40,792
-27% -$1.29M 0.06% 236
2022
Q3 		$4.75M Sell
148,971
-22,002
-13% -$808K 0.11% 173
2022
Q2 		$6.41M Buy
170,973
+6,698
+4% +$234K 0.14% 149
2022
Q1 		$7.01M Sell
164,275
-19,750
-11% -$942K 0.14% 150
2021
Q4 		$9.98M Sell
184,025
-14,807
-7% -$1.02M 0.17% 119
2021
Q3 		$14.6M Sell
198,832
-8,514
-4% -$714K 0.26% 81
2021
Q2 		$17.9M Buy
207,346
+5,957
+3% +$506K 0.32% 79
2021
Q1 		$17.9M Buy
201,389
+47,053
+30% +$4.67M 0.68% 39
2020
Q4 		$14.4M Buy
154,336
+45,628
+42% +$3.64M 0.57% 37
2020
Q3 		$6.93M Buy
108,708
+48,098
+79% +$2.82M 0.32% 55
2020
Q2 		$3.16M Buy
60,610
+33,698
+125% +$1.45M 0.2% 76
2020
Q1 		$842K Buy
26,912
+9,331
+53% +$312K 0.05% 175
2019
Q4 		$589K Buy
17,581
+7,387
+72% +$235K 0.03% 259
2019
Q3 		$301K Buy
+10,194
New +$331K 0.02% 342
2018
Q4 		– Sell
-27,504
Closed -$919K – 313
2018
Q3 		$919K Buy
+27,504
New +$871K 0.07% 184

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Brookstone Capital Management's ARKG Position: Q2 2026 in Review

Brookstone Capital Management increased its ARK Genomic Revolution ETF (ARKG) stake by 13% in Q2 2026, buying an estimated $159K and bringing the position to 44,330 shares worth $1.86M. The position accounts for 0.02% of the portfolio, ranked #514.

Brookstone Capital Management first reported a position in ARKG in Q3 2018 and has held it in 29 quarters since. The position peaked at $17.9M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Brookstone Capital Management held 44,330 shares of ARK Genomic Revolution ETF worth $1.86M as of Q2 2026.
  • Brookstone Capital Management bought 4,979 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $159K.
  • ARK Genomic Revolution ETF made up 0.02% of Brookstone Capital Management's portfolio in Q2 2026, its #514 holding.
  • Brookstone Capital Management first reported a position in ARK Genomic Revolution ETF in Q3 2018 and has held it in 29 quarters since.
  • Brookstone Capital Management's ARK Genomic Revolution ETF position peaked at $17.9M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.